W
WAVEMAN · COMPANY
NVCR · Novocure Ltd
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

NVCR

NovoCure Ltd
MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001645113
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$939.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
124
13F, latest reported quarter
REVENUE GROWTH
+8.3%
XBRL, annual
NET MARGIN
-20.8%
CONVERSIONS · 180D
1
codes C/M, not in net · $244.9K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$939.6K over 180 days
below 60% of Medical Devices
CONGRESS
no member of Congress has reported trading it
FUNDS
124 funds added or opened last quarter
more than 62% of Medical Devices
REVENUE
+8.3% year over year
more than 52% of Medical Devices
MARGIN
-20.8% net margin
below 60% of Medical Devices
BUYBACKS
no share repurchases reported
SHORT
8.7% of shares outstanding short · 4.9 days to cover · settled 2026-07-31
more than 84% of Medical Devices
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$939.6K across 8 people in 180 days.
124 funds added or opened positions in the latest 13F quarter, of 220 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +47.2%
+47.2%12M
-18%+10%+37%+64%2025-092025-102025-122026-032026-052026-072026-09 2025-09-05 · Cordova Ashley bought $996.5K2026-03-03 · DOYLE WILLIAM F sold $646.6K2026-06-04 · Leonard Frank X sold $614.5K2026-03-05 · Paravasthu Mukund sold $595.5K2026-03-03 · DOYLE WILLIAM F sold $286.5K2026-02-27 · Leonard Frank X sold $133.0K2026-02-27 · Weinberg Uri sold $103.3K2026-03-02 · Leonard Frank X sold $97.6K2026-03-04 · Weinberg Uri sold $85.3K2026-03-04 · Brackmann Christoph sold $85.3K2026-03-04 · Leonard Frank X sold $74.6K2026-03-04 · Paravasthu Mukund sold $71.6K2026-06-02 · LEUNG GABRIEL sold $46.4K2026-06-02 · Stafford Kristin sold $46.4K2026-06-02 · Ocean Allyson J sold $46.4K2026-06-02 · Scannell Timothy J sold $46.4K2026-06-02 · HILLEMAN JERYL L sold $46.4K2026-06-02 · VERNON W ANTHONY sold $46.4K2026-06-02 · Hung David sold $46.4K2026-03-02 · Weinberg Uri sold $43.6K2026-02-27 · Paravasthu Mukund sold $21.2K2026-02-27 · Puri Michal Nath sold $19.7K2026-03-04 · Leupin Nicolas sold $14.6K2026-03-04 · Puri Michal Nath sold $14.6K2026-02-27 · Leupin Nicolas sold $14.1K2026-03-02 · Paravasthu Mukund sold $5.5K2026-07-23 · NICOLAS LEUPIN filed to sell $608.6K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $939.6K sold by insiders over 180 days, 124 funds added last quarter, $608.6K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
TMOPENROKBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDX
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, NovoCure Ltd insiders sold a net $939.6K of stock across 233 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Leonard Frank X
Chief Executive Officer
SELL
2026-06-04
34,273.0
$614.5K
LEUNG GABRIEL
Director
SELL
2026-06-02
2,945.0
$46.4K
Stafford Kristin
Director
SELL
2026-06-02
2,945.0
$46.4K
Ocean Allyson J
Director
SELL
2026-06-02
2,945.0
$46.4K
Scannell Timothy J
Director
SELL
2026-06-02
2,945.0
$46.4K
233 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 228 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
17,373,078.0 sh
$263.2M
BlackRock, Inc.
13,413,699.0 sh
$203.2M
Soleus Capital Management, L.P.
9,913,401.0 sh
$150.2M
VANGUARD PORTFOLIO MANAGEMENT LLC
6,272,490.0 sh
$95.0M
VANGUARD CAPITAL MANAGEMENT LLC
4,903,633.0 sh
$74.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
NICOLAS LEUPIN
FILED 2026-07-23
$608.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ROBO Global Healthcare Technology and Innovation ETF
$1.1M POSITION · AS OF 2026-04-30
2.0%
Global X HealthTech ETF
$611.0K POSITION · AS OF 2026-02-28
1.7%
Invesco NASDAQ Future Gen 200 ETF
$70.4K POSITION · AS OF 2026-02-28
0.5%
T. Rowe Price Health Care ETF
$93.7K POSITION · AS OF 2026-03-31
0.5%
NORTH SQUARE DYNAMIC SMALL CAP FUND
$2.4M POSITION · AS OF 2026-02-28
0.3%
Nuveen Quant Small Cap Equity Fund
$9.6M POSITION · AS OF 2026-04-30
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 9 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
2
Phase 2
0 ACTIVE
2
Phase 3
0 ACTIVE
5
Not applicable
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Novocure Inc. Pac (A.K.A. Novocure Pac)
CYCLE 2026 · $160K SPENT
$125.9K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Executive pay vs shareholder return · Mr. Danziger
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$1.5M
$796.2K
$5.4M
-65%
+18%
2023
$1.5M
-$5.2M
$5.5M
-82%
+19%
2022
$2.3M
$2.1M
$6.5M
-13%
+14%
2021
$1.2M
-$31.5M
$5.7M
-11%
+26%
2020
$9.0M
$53.3M
$7.4M
+105%
+26%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$655.4M$605.2M$509.3M$537.8M
GROSS PROFIT$488.5M$468.0M$381.1M$423.0M
OPERATING INCOME$-153.8M$-170.5M$-232.9M$-89.5M
NET INCOME$-136.2M$-169.0M$-207.0M$-93.0M
EPS (DILUTED)-1.22-1.56-1.95-0.88
OPERATING CASH FLOW$-49.0M$-26.4M$-73.3M$30.8M
CASH$93.5M$163.8M$240.8M$115.3M
LONG-TERM DEBT$195.0M$97.3M$568.8M$565.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →